학술논문
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma
Document Type
Article
Author
Yamamoto, Chihiro; Minakata, Daisuke; Koyama, Shunsuke; Sekiguchi, Kaoru; Fukui, Yuta; Murahashi, Rui; Nakashima, Hirotomo; Matsuoka, Sae; Ikeda, Takashi; Kawaguchi, Shin-ichiro; Toda, Yumiko; Ito, Shoko; Nagayama, Takashi; Umino, Kento; Nakano, Hirofumi; Morita, Kaoru; Yamasaki, Ryoko; Ashizawa, Masahiro; Ueda, Masuzu; Hatano, Kaoru; Sato, Kazuya; Ohmine, Ken; Fujiwara, Shin-ichiro; Kanda, Yoshinobu
Source
In Blood 11 August 2022 140(6):594-607
Subject
Language
ISSN
0006-4971